Press Releases
June 15, 2007
Gilead Sciences to Host Conference Call to Discuss the U.S. Food and Drug Administration Approval of Letairis(TM)
FOSTER CITY, Calif.--(BUSINESS WIRE)--June 15, 2007--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that management of the company will host a pre-recorded conference call to discuss the U.S. Food and Drug Administration approval of Letairis(TM) (ambrisentan) 5 mg and 10 mg tablets on Friday June 15, 2007 at 2:30 p.m. Pacific time / 5:30 p.m. Eastern time. Letairis is an endothelin receptor antagonist (ERA) indicated for the once-daily treatment of pulmonary arterial hypertension (WHO Group 1) in patients with WHO Functional Class II or III symptoms to improve exercise capacity and delay clinical worsening. The conference call will be webcast through the company's website at www.gilead.com and will feature John C. Martin, PhD, President and Chief Executive Officer; John F. Milligan, PhD, Chief Operating Officer and Chief Financial Officer; and Kevin Young, Executive Vice President of Commercial Operations.
It is recommended that those interested in accessing the webcast go to the Gilead website at least 10 minutes in advance of the call to download any applicable software. An archived webcast will be available for 5 days, and a phone replay will be available through June 20, 2007, by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering the passcode 67654510.
About Gilead
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
For more information on Gilead Sciences, please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).
CONTACT: Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
SOURCE: Gilead Sciences, Inc.